I’ve gotten more mail about GLP-1 medications in the last six months than any other topic. Most of it isn’t “does it work” — people have seen the clinical trial numbers. The questions are about what actually happens to real people over a longer period of time.

I’ve been compiling what I find: reader experiences, longitudinal studies, survey data, and the kinds of things that show up in the medical literature but don’t make the mainstream press.

Here’s what I’ve found.

What most people say about the first three months

The first few months are a consistent experience across a lot of accounts:

The nausea is real. Roughly 40–50% of people experience nausea, especially during dose increases. For most, it improves substantially after 4–8 weeks. For some, it doesn’t go away entirely until they find a dose that balances efficacy with tolerability.

The “food noise” reduction is the thing people talk about most. This is a consistent theme in patient surveys and reader mail. “Food noise” refers to the constant mental chatter about food — thinking about the next meal, craving specific things, negotiating with yourself about what to eat. Many people report this significantly diminishing or disappearing.

A 2024 survey study published in Obesity found that among 1,580 people who had been on GLP-1 medications for at least 6 months, the most commonly reported unexpected benefit was “reduced preoccupation with food” — cited by 71% of respondents.

Weight loss is fastest in months 2–5, then slows. Most people hit a plateau around months 4–6, even at the maximum dose. The plateau is real and tends to cause distress. The research suggests this is a normal dose-response effect — weight loss doesn’t continue indefinitely at any given dose.

What happens between months 6 and 12

This is the period that gets less attention.

Tolerability improves for most. By 6 months, the GI side effects have usually settled. The people who are still on the medication at 6 months are generally a self-selected group that found a tolerable dose and dosing schedule.

Muscle loss concerns emerge here. Rapid weight loss from any cause includes some loss of lean muscle mass. Studies suggest people on GLP-1 medications lose roughly 25–40% of their total weight loss from lean mass rather than fat mass alone. This is comparable to other weight loss methods, but it’s not zero.

The intervention that the research consistently recommends: resistance training while on these medications. People who lifted weights while taking semaglutide in a 2024 trial maintained significantly more muscle mass than those who didn’t, with similar total weight loss.

Some people stop. The discontinuation rates in longer follow-up periods are higher than in clinical trials. Common reasons: GI side effects that don’t resolve, cost (most insurance doesn’t cover these medications), and in some cases the medication stops being effective.

The weight regain question

This is the hardest part to write about without being either misleading or discouraging.

The data is clear: when people stop these medications, most of the weight returns. The 2022 follow-up study I mentioned in the GLP-1 overview piece showed about two-thirds of lost weight returning within 12 months of stopping.

This isn’t because the medication “stopped working.” It’s because the medication was doing the work. When you stop, the work stops.

The implications are worth thinking through before starting:

  1. If cost is an issue, what happens when you can no longer afford the medication?
  2. If insurance coverage changes, what’s the plan?
  3. Are you prepared for this to be a long-term commitment, similar to blood pressure medication?

None of this means you shouldn’t start. It means you should go in clear-eyed about what you’re committing to.

What the research doesn’t cover well yet

Cognitive effects. A number of people report changes in their relationship with food that feel psychological as much as physical — reduced impulsive eating, less emotional eating, different relationship with reward. The research on GLP-1 receptors in the brain is still emerging.

Long-term cardiovascular effects in non-diabetic populations. The SELECT trial showed impressive cardiovascular protection in people with diabetes and obesity. The data for people with obesity but without diabetes is still being collected.

What happens to weight setpoint after 2–3+ years on the medication. We simply don’t have enough long-term data yet. The trials have mostly run to 2 years.


If you’re considering these medications, the program comparison I wrote has the current information on telehealth options, pricing, and what to watch out for.


This content is for educational purposes only and is not medical advice. GLP-1 medications require a prescription and medical supervision. Individual experiences vary. Consult your healthcare provider for personalized guidance.